70.84MMarket Cap-526P/E (TTM)
0.673High0.632Low581.02KVolume0.656Open0.657Pre Close382.47KTurnover0.58%Turnover RatioLossP/E (Static)108.57MShares3.33052wk High5.06P/B65.34MFloat Cap0.52052wk Low--Dividend TTM100.14MShs Float35.200Historical High--Div YieldTTM6.18%Amplitude0.520Historical Low0.658Avg Price1Lot Size
Gritstone Bio Stock Forum
NEWS
Gritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024
NEWS
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
-- Paper details vaccine design optimization process of Gritstone’s “off-the-shelf” or shared neoantigen vaccine platform, SLATE --
-- Discovery of a novel immunodominance hierarchy of tumor neoantigens (including KRAS) enabled the development of a more potent, KRAS-specific vaccine candidate (SLATE-KRAS) being studied by Steven A. ...
No comment yet